Neurocrine’s depression treatment misses main goal in Phase II study
The aim was to measure depression severity change from baseline to day five using the Montgomery-Åsberg Depression Rating Scale.
Drug Development
China accounts for one-fifth of global drugs in development
Imunon’s Phase III-stage IL-12 gene therapy alters tumour microenvironment in ovarian cancer
Four drugs race for first bispecific ADC approval
NKGen activates new sites for Phase I/IIa study of Alzheimer’s cell therapy
Astellas and Evopoint sign ADC licensing deal
Daiichi Sankyo and MSD withdraw US BLA for lung cancer treatment
CHMP recommends GSK’s Blenrep approval for multiple myeloma treatment
